DanielleReneeSterrenbergMD(She/Her)

Oncology • Pasadena, CA

Hematologic Oncology

Clinical Associate Professor of Medicine

Join to view full profile

Dr. Sterrenberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sterrenberg's full profile

Already have an account?

Office
625 S Fair Oaks Ave
Pasadena, CA 91105
Is this information wrong?

Summary

Dr. Danielle Sterrenberg is an oncologist in Pasadena, CA and is affiliated with USC Norris Comprehensive Cancer Center. She received her medical degree from University of Arkansas for Medical Sciences (UAMS) College of Medicine and has been in practice 8 years. She specializes in hematologic oncology and is experienced in gastrointestinal cancer, pancreatic cancer, breast cancer, lung cancer, and head and neck cancer.

Education & Training

Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2009 - 2012
University of Arkansas For Medical Sciences College of MedicineClass of 2009

Certifications & Licensure

CA State Medical License 2021 - 2025
IL State Medical License 2009 - 2023
IN State Medical License 2015 - 2017

Awards, Honors, & Recognition

Magis Star Loyola University, 2013
Resident Teaching Award Northwestern University, 2011-2012
Alpha Omega Alpha 2009

Clinical Trials

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Start of enrollment: 2018 Jun 25
Recruiting
Phase 2
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS Start of enrollment: 2017 Feb 22
Active, not recruiting
Not Applicable

Publications & Presentations

PubMed

96 citations
Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
Andrew M. Evens, Rupali Roy, Danielle Sterrenberg, Michelle Z. Moll, Amy Chadburn
Current Oncology Reports. 2010-10-21
27 citations
Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Tulio E. Rodriguez, Parameswaran Hari, Patrick J. Stiff, Scott E. Smith, Danielle Sterrenberg
Biology of Blood and Marrow Transplantation. 2016-08-01

Press Mentions

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01February 15th, 2024

Research History

Principal Investigator- UChicago Medicine, Ingalls Memorial Hospital16-0403 A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-bound Paclitaxel (nab-paclitaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer.2021 - 2022
Principal Investigator: UChicago Medicine, Ingalls Memorial HospitalSGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer2021 - 2021
Principal Investigator: UChicago Medicine, Ingalls Memorial HospitalS1418 Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemo2021 - 2021
Principal Investigator: UChicago Medicine, Ingalls Memorial HospitalI3Y-MC-JPCX: Single-Arm Phase 4 Study of Abemaciclib (CDK 4 & 6 Inhibitor) w/Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Pts w/Hormone Receptor Pos, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Ca w/Poor Prognostic Factors2021 - 2021
Principal InvestigatorAn Open-Label, Multicenter, Long-Term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/Tesaro-Sponsored Niraparib Study and are Judged by the Investigator to Benefit from Continued Treatment with Niraparib2020 - 2021
Principal Investigator: UChicago Medicine, Ingalls Memorial Hospital3000-02-001: Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer2020 - 2021
Principal Investigator: UChicago Medicine, Ingalls Memorial HospitalS1904: Cluster Randomized Controlled Trial Pt & Provider Decision Support to Increase Chemoprevention Informed Choice Among Women w/Atypical Hyperplasia or Lobular Carcinoma in Situ: Making Informed Choices on Incorporating Chemoprevention into Care MiCHOICE2020 - 2021
Principal Investigator: UChicago Medicine, Ingalls Memorial HospitalA011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib2020 - 2021
Principal Investigator- UChicago Medicine, Ingalls Memorial Hospital17-0721: Phase II Study of Pembrolizumab and Mifepristone in Patients with Advanced HER2-Negative Breast Cancer2020 - 2021
Principal Investigator: UChicago Medicine, Ingalls Memorial HospitalSGNTV-001: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019 - 2021
Principal Investigator- UChicago Medicine, Ingalls Memorial HospitalGY023 Randomized Phase II Trial of Triplet (Durvalumab+Olaparib+Cediranib) Compared to Olaparib+Cediranib or Durvalumab+Cediranib or SOC in Women with Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Ca Who Received Prior Bev2019 - 2021